Literature DB >> 7379758

Calcitonin-like immunoreactivity in rat and human pituitary glands: histochemical, in vitro, and in vivo studies.

C W Cooper, T C Peng, J F Obie, S C Garner.   

Abstract

This study was designed to determine whether pituitary glands contain an immunoreactive material which reacts with antisera to calcitonin (CT) and, if so, whether secretion of the material could be demonstrated. Testing 15 antisera to rat and human CT and using an immunoperoxidase method, we found 2 antisera to human CT which stained rat pituitaries and several which stained human pituitaries. Essentially all cells in the rat intermediate lobe and scattered cells in the rat and human anterior lobes showed staining, and staining was not entirely abolished by prior adsorption of antisera with rat or human CT. The 2 antisera which stained rat pituitaries showed cross-reactivity with several synthetic human CT fragments (1-18, 11-23 and 22-32) but not with ACTH-(1-39), ACTH-(1-24), beta-endorphin, alpha- or beta MSH, or bovine lipotropin. Crude extracts of pituitaries from 2 strains of young rats showed CT-like immunoreactivity which could be measured easily by RIA (0.2-0.3 ng/gland). In vivo, an antiserum which stained pituitaries and 1 which did not were compared using young rats made hypercalcemic (15-20 mg/dl) with iv Ca. In rats with thyroids, both antisera showed an increase in serum CT of more than 15-fold whether the pituitary was present or absent. In thyroidectomized rats, serum CT remained undetectable (less than 50 to 100 pg/ml) during hypercalcemia even if the pituitary was present. In vitro, rat pituitaries in a serum-free medium did not release measurable amounts of immunoreactive CT-like material even when medium contained high Ca (2.5 mM), high K (25 mM), or TRH (10(-6) M). Therefore, the findings agree with other reports of a CT-like material in the pituitary, but no secretion of the material could be demonstrated. We hypothesize that the material is not authentic CT but is, rather a related peptide sequence probably contained in the 31 K precursor protein of ACTH-beta-lipotropin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7379758     DOI: 10.1210/endo-107-1-98

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  High serum calcitonin levels in heroin addicts.

Authors:  F Tagliaro; F Capra; R Dorizzi; G Luisetto; A Accordini; E Renda; A Parolin
Journal:  J Endocrinol Invest       Date:  1984-08       Impact factor: 4.256

2.  Does calcitonin modulate anterior pituitary hormone secretion?

Authors:  G P Ceda; G Valenti; E Dall'Aglio; E Palummeri; D Provvedini; U Butturini
Journal:  J Endocrinol Invest       Date:  1982 Sep-Oct       Impact factor: 4.256

3.  Immunoreactive calcitonin in brain regions and pituitary of sheep.

Authors:  S Balabanova; O King; R Nowak; H Sachs; D Leupold
Journal:  J Endocrinol Invest       Date:  1985-10       Impact factor: 4.256

4.  Calcitonin: regional distribution of the hormone and its binding sites in the human brain and pituitary.

Authors:  J A Fischer; P H Tobler; M Kaufmann; W Born; H Henke; P E Cooper; S M Sagar; J B Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

5.  Extraction of a substance with calcitonin-like immunoreactivity from pituitary glands of intact and thyroidectomized rats.

Authors:  H G Bone; B D Catherwood; L J Deftos
Journal:  Calcif Tissue Int       Date:  1983-07       Impact factor: 4.333

6.  Alternative RNA processing events in human calcitonin/calcitonin gene-related peptide gene expression.

Authors:  V Jonas; C R Lin; E Kawashima; D Semon; L W Swanson; J J Mermod; R M Evans; M G Rosenfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

7.  A synthetic peptide derived from mouse pituitary calcitonin cDNA sequence exhibits potent inhibition of prolactin secretion and prolactin mRNA abundance in primary mouse pituitary cells.

Authors:  Trupti Kulkarni-Paranjape; Girish V Shah
Journal:  Endocrine       Date:  2007-06       Impact factor: 3.633

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.